FDA outlines faster approval route for custom gene therapies
The Food and Drug Administration's move drew applause from rare disease advocates seeking quicker access to treatments.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
The Food and Drug Administration has released new details on a faster approval pathway for personalized gene therapies. Rare disease advocates applauded the move to speed patients' access to treatments.
Why it matters
The change is aimed at getting treatments to people with rare diseases more quickly.
Coverage
- FDA offers new details on quicker approval pathway for personalized gene therapies (statnews.com)
- Medical research is worth the effort (northernstar.info)
More from Health
- Lancet study urges climate change be declared global health emergency
- NIH launches new vaccine injury center under HHS initiative
- Researchers propose six areas to strengthen ClinicalTrials.gov
- Georgia health officials confirm three new measles cases
- Arizona providers warn Medicaid cuts will crowd emergency rooms
- Artiva halts autoimmune cell therapy and cuts 94% of staff